Pesquisas alternativas:
disease living » disease moving (Expandir a Pesquisa), disease leading (Expandir a Pesquisa), disease long (Expandir a Pesquisa)
does develop » boys develop (Expandir a Pesquisa), loss develop (Expandir a Pesquisa), does developing (Expandir a Pesquisa)
develop type » developing type (Expandir a Pesquisa)
drug disease » lung disease (Expandir a Pesquisa), drug release (Expandir a Pesquisa)
living ther » living mother (Expandir a Pesquisa), living theory (Expandir a Pesquisa), living third (Expandir a Pesquisa)
drug noise » drug naive (Expandir a Pesquisa), drug nurse (Expandir a Pesquisa), during noise (Expandir a Pesquisa)
level ther » level theory (Expandir a Pesquisa), level rather (Expandir a Pesquisa), levels other (Expandir a Pesquisa)
drug does » drug doses (Expandir a Pesquisa), drugs does (Expandir a Pesquisa), drug dose (Expandir a Pesquisa)
disease living » disease moving (Expandir a Pesquisa), disease leading (Expandir a Pesquisa), disease long (Expandir a Pesquisa)
does develop » boys develop (Expandir a Pesquisa), loss develop (Expandir a Pesquisa), does developing (Expandir a Pesquisa)
develop type » developing type (Expandir a Pesquisa)
drug disease » lung disease (Expandir a Pesquisa), drug release (Expandir a Pesquisa)
living ther » living mother (Expandir a Pesquisa), living theory (Expandir a Pesquisa), living third (Expandir a Pesquisa)
drug noise » drug naive (Expandir a Pesquisa), drug nurse (Expandir a Pesquisa), during noise (Expandir a Pesquisa)
level ther » level theory (Expandir a Pesquisa), level rather (Expandir a Pesquisa), levels other (Expandir a Pesquisa)
drug does » drug doses (Expandir a Pesquisa), drugs does (Expandir a Pesquisa), drug dose (Expandir a Pesquisa)
1
Por Ritchwood, Tiarney D., DeCoster, Jamie, Metzger, Isha, Bolland, John M., Danielson, Carla K.
Publicado no Addict Behav (2016)
“... the consideration of type of SU, and particular combinations of substances, on RSBs in intervention development....”Publicado no Addict Behav (2016)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
2
Por Jacob, Stefanie, Dötsch, Andreas, Knoll, Sarah, Köhler, Heinz-R., Rogall, Eike, Stoll, Dominic, Tisler, Selina, Huhn, Carolin, Schwartz, Thomas, Zwiener, Christian, Triebskorn, Rita
Publicado no Environ Sci Eur (2018)
“...BACKGROUND: Due to the rising number of type 2 diabetes patients, the antidiabetic drug, metformin...”Publicado no Environ Sci Eur (2018)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
3
Por Kenney, Jessica, Derby, Nina, Aravantinou, Meropi, Kleinbeck, Kyle, Frank, Ines, Gettie, Agegnehu, Grasperge, Brooke, Blanchard, James, Piatak, Michael, Lifson, Jeffrey D., Zydowsky, Thomas M., Robbiani, Melissa
Publicado em 2014
Assuntos:
“...Preclinical Studies/Drug Development...”Publicado em 2014
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
4
Por Kagan, Ron M., Johnson, Erik P., Siaw, Martin F., Van Baelen, Ben, Ogden, Richard, Platt, Jamie L., Pesano, Rick L., Lefebvre, Eric
Publicado em 2014
Assuntos:
“...Preclinical Studies/Drug Development...”Publicado em 2014
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
5
Por Simon, Richard
Publicado em 2013
“... human diseases presents new opportunities to develop more effective treatments and new challenges...”Publicado em 2013
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
6
“...The pharmaceutical industry is progressively operating in an era where development costs...”
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
7
Por Kapitza, Christoph, Nosek, Leszek, Jensen, Lene, Hartvig, Helle, Jensen, Christine B, Flint, Anne
Publicado no J Clin Pharmacol (2015)
Assuntos:
“...Drug Interactions...”Publicado no J Clin Pharmacol (2015)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
8
Por Gentile, Giulia, Ceccarelli, Manuela, Micheli, Laura, Tirone, Felice, Cavallaro, Sebastiano
Publicado no Front Pharmacol (2016)
“...., the neural cell type involved in group 3 MB; (iii) the identification of a subset of putative drug targets...”Publicado no Front Pharmacol (2016)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
9
Por Ptaszynska, Agata, Cohen, Samuel M., Messing, Edward M., Reilly, Timothy P., Johnsson, Eva, Johnsson, Kristina
Publicado no Diabetes Ther (2015)
“... in drug development programs in patients with type 2 diabetes mellitus (T2DM). METHODS: Clinical cases...”Publicado no Diabetes Ther (2015)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
10
Por Wesnes, Keith A.
Publicado em 2000
“... of the core deficits of Alzheimer's disease can be used to screen potential antidernentia drugs. Ultimately...”Publicado em 2000
Obter o texto integral
Obter o texto integral
Artigo
11
Por Guo, Qingjie, Zheng, Ruonan, Huang, Jiarui, He, Meng, Wang, Yuhan, Guo, Zonghao, Sun, Liankun, Chen, Peng
Publicado no Front Genet (2018)
“.... In this study, we applied an integrative analysis approach, aiming to prioritize the drug development candidate...”Publicado no Front Genet (2018)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
12
Por Nagaraj, Geetha, Ganaie, Feroze, Govindan, Vandana, Ravikumar, Kadahalli Lingegowda
Publicado no Pneumonia (Nathan) (2017)
“...BACKGROUND: Precise serotyping of pneumococci is essential for vaccine development, to better...”Publicado no Pneumonia (Nathan) (2017)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
13
“..., in the development of delayed-type drug hypersensitivity reactions in skin. As keratinocytes have been shown to play...”
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
14
Por McCarthy, D. M.
Publicado em 1998
“...1. H. pylori gastritis appears to increase the likelihood of developing dyspeptic symptoms on NSAID...”Publicado em 1998
Obter o texto integral
Obter o texto integral
Artigo
15
“... associated with clients' type of drug use (i.e., stable vs. chaotic), where more stable drug use...”
Obter o texto integral
Obter o texto integral
Artigo
16
“... with clients' type of drug use (i.e., stable vs. chaotic), where more stable drug use was associated...”
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
17
Por Kou, Longfa, Bhutia, Yangzom D., Yao, Qing, He, Zhonggui, Sun, Jin, Ganapathy, Vadivel
Publicado no Front Pharmacol (2018)
“... are expressed at higher than normal levels in selective cell types under pathological conditions. They also play...”Publicado no Front Pharmacol (2018)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
18
Por Dhama, Kuldeep, Karthik, Kumaragurubaran, Khandia, Rekha, Chakraborty, Sandip, Munjal, Ashok, Latheef, Shyma K., Kumar, Deepak, Ramakrishnan, Muthannan Andavar, Malik, Yashpal Singh, Singh, Rajendra, Malik, Satya Veer Singh, Singh, Raj Kumar, Chaicumpa, Wanpen
Publicado no Front Immunol (2018)
“... in designing and developing vaccines, drugs, and therapies to counter the EBOV threat....”Publicado no Front Immunol (2018)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
19
Por Nebeker, J. R., Hurdle, J. F., Hoffman, J., Roth, B., Weir, C. R., Samore, M. H.
Publicado em 2001
“...Computerized decision support and order entry shows great promise for reducing adverse drug events...”Publicado em 2001
Obter o texto integral
Obter o texto integral
Artigo
20
Por Scherer, Constanze R, Lerche, Christian, Decher, Niels, Dennis, Adrienne T, Maier, Patrick, Ficker, Eckhard, Busch, Andreas E, Wollnik, Bernd, Steinmeyer, Klaus
Publicado em 2002
“... patient reported to develop fexofenadine-associated LQTS. 3. K897T HERG channels produced wild-type-like...”Publicado em 2002
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo